Does low intensity laser therapy reduce pain and change orofacial myofunctional conditions?

Due to its multifactorial pain aspects, combined therapies are required for the the comprehensive management of temporomandibular joint disorders (TMD). Interdisciplinary forms of therapies, such as laser therapy, and health care or medical professionals, such as speech therapists, have been proposed for this comprehensive management. The aims of this study were the following: 1. verify whether low-intensity laser therapy would promote significant pain remission; 2. evaluate whether this changes orofacial myofunctional conditions in the sample, as tested, using the Orofacial Myofunctional Evaluation with Scores (OMES); and 3. evaluate whether or not the pain improvement would remain stable after a 30-day follow-up for pain conditions. The study included 12 female volunteers diagnosed with myofascial pain and ages ranging from 18 to 60 years old, with or without intra-articular TMD, according to axis I of the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD). Participants were assessed for pain on palpation, using a visual analogue scale (VAS), before treatment (A1), immediately after 30 days of intervention, i.e, after eight sessions of Low Intensity Laser Therapy (LILT) (A2), and 30 days after the end of the treatment with LILT (A3) (follow-up). Comparing the three evaluation times, it was observed that there was a significant decrease in the values of subjective pain to palpation (p < 0.05). The initial pain (A1) differed significantly from the A2, but did not differ significantly from A3.

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

PURPOSE: To report the long-term results of the Intergroup Radiation Therapy Oncology Group 91-11 study evaluating the contribution of chemotherapy added to radiation therapy (RT) for larynx preservation. PATIENTS AND METHODS: Patients with stage III or IV glottic or supraglottic squamous cell cancer were randomly assigned to induction cisplatin/fluorouracil (PF) followed by RT (control arm), concomitant cisplatin/RT, or RT alone. The composite end point of laryngectomy-free survival (LFS) was the primary end point. RESULTS: Five hundred twenty patients were analyzed. Median follow-up for surviving patients is 10.8 years. Both chemotherapy regimens significantly improved LFS compared with RT alone (induction chemotherapy v RT alone: hazard ratio [HR], 0.75; 95% CI, 0.59 to 0.95; P = .02; concomitant chemotherapy v RT alone: HR, 0.78; 95% CI, 0.78 to 0.98; P = .03). Overall survival did not differ significantly, although there was a possibility of worse outcome with concomitant relative to induction chemotherapy (HR, 1.25; 95% CI, 0.98 to 1.61; P = .08). Concomitant cisplatin/RT significantly improved the larynx preservation rate over induction PF followed by RT (HR, 0.58; 95% CI, 0.37 to 0.89; P = .0050) and over RT alone (P < .001), whereas induction PF followed by RT was not better than treatment with RT alone (HR, 1.26; 95% CI, 0.88 to 1.82; P = .35). No difference in late effects was detected, but deaths not attributed to larynx cancer or treatment were higher with concomitant chemotherapy (30.8% v 20.8% with induction chemotherapy and 16.9% with RT alone). CONCLUSION: These 10-year results show that induction PF followed by RT and concomitant cisplatin/RT show similar efficacy for the composite end point of LFS. Locoregional control and larynx preservation were significantly improved with concomitant cisplatin/RT compared with the induction arm or RT alone. New strategies that improve organ preservation and function with less morbidity are needed.

Recovery of swallowing function is accompanied by the expansion of the cortical map.

To determine whether multiple sessions of electrical stimulation (ES) applied to neck muscles improve swallowing function and whether this improvement is accompanied by cortical reorganization in patients with dysphagia, before-after trials were performed on eight subjects. ES was applied for 1 hour, 5 days a week for 2 weeks. Swallowing function significantly improved after 2 weeks of ES, and this change was found to correlate with cortical reorganization measured by corticobulbar output maps. This study suggests that multiple sessions of ES applied to the neck muscles improve swallowing function via a mechanism involving long-term cortical reorganization.

[The radiochemotherapy of the oesophageal cancer]. / A nyelôcsôrák szimultán radio-kemoterápiája (saját eredményeink alapján).

AIM: To prove the efficacy of the simultaneous radio-chemotherapy of the inoperable or non-resectable esophageal cancer. METHODS: Twenty-nine patients with inoperable or non-resectable oesophageal cancer were treated between January 1995 and December 2002. The therapy was started with intraluminal HDR AL irradiation for the recanalisation of the esophagus (8 Gy at 0.5 cm depth, repeated two-three times, with one-week interval), followed by percutaneous megavolt irradiation one week after the last HDR AL session (50 Gy total dose, 5 x 2 Gy/week fractions for 5 weeks). The chemotherapy was started simultaneously with the percutaneous megavolt irradiation (three courses of Cisplatin-5-Fluorouracil combination, with four-week intervals). RESULTS: The swallow function has been improved in 16/29 patients, it remained unchanged in 10/29 and got worse in 3/29 patients (1 and 3 Units), respectively. REMISSION: complete 9/29 patients, partial 17/29 patients. Side effects: Esophagitis of different degree occurred in all patients, consecutive transitory dysphagia developed in 8/29 patients, leucopenia after the chemotherapy in 2/29 patients, tracheo-esophageal fistula in 3/29 patients. Follow-up time: average 12.2 months (3-55 months). The duration of the swallow function improvement: average 10.7 months (2-55 months). CONCLUSION: The initial results refer to the favourable effect of the palliative radio-chemotherapy of the inoperable esophageal cancer.

Evaluation and management of oropharyngeal Dysphagia in head and neck cancer.

BACKGROUND: Dysphagia is a common symptom of head and neck cancer or sequelae of its management. Swallowing disorders related to head and neck cancer are often predictable, depending on the structures or treatment modality involved. Dysphagia can profoundly affect posttreatment recovery as it may contribute to aspiration pneumonia, dehydration, malnutrition, poor wound healing, and reduced tolerance to medical treatments. METHODS: The author reviewed the normal anatomy and physiology of swallowing and contrasted it with the commonly identified swallowing deficits related to head and neck cancer management. Evaluation methods and treatment strategies that can be used to successfully manage the physical and psychosocial effects of dysphagia are also reviewed. RESULTS: Evaluation of dysphagia by the speech pathologist can be achieved with instrumental and noninstrumental methods. Once accurate identification of the deficits is completed, a range of treatment strategies can be applied that may return patients to safe oral intake, improve nutritional status, and enhance quality of life. CONCLUSIONS: To improve safety of oral intake, normalize nutritional status, reduce complications of cancer treatment and enhance quality of life, accurate identification of swallowing disorders and efficient management of dysphagia symptoms must be achieved in an interdisciplinary team environment.